SAN DIEGO, Nov. 15, 2016 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, today
announced that the Company will host its fiscal first quarter 2017
financial results conference call on Thursday, December 8 at 1:15 PM PT/4:15 PM
ET. To listen to the conference call, please dial (877)
731-1960 and use conference ID number: 18899796. An archived
version of the presentation will be available for 90 days on the
"Investors" section of OncoSec's website:
ir.oncosec.com/events-presentations.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse®,
for the treatment of cancer. ImmunoPulse® is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse® IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various solid
tumors as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse® IL-12, is currently
in clinical development for several indications, including
metastatic melanoma, head and neck cancer, and triple-negative
breast cancer. The program's current focus is on the significant
unmet medical need in patients with melanoma who are refractory or
non-responsive to anti-PD-1/PD-L1 therapies. In addition to
ImmunoPulse® IL-12, the Company is also identifying and developing
new immune-targeting agents for use with the ImmunoPulse® platform.
For more information, please visit www.oncosec.com.
Contact
Sophia Ononye,
PhD MPH MBA
Associate Director, Investor Relations and Corporate
Communications
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-host-first-quarter-financial-results-conference-call-on-december-8-2016-300362972.html
SOURCE OncoSec Medical Incorporated